June 23, 2017 / 11:38 AM / 2 months ago

BRIEF-European CHMP adopts positive opinion for Gilead's Vosevi

June 23 (Reuters) - Gilead Sciences Inc:

* European CHMP adopts positive opinion for Gilead's Vosevi (sofosbuvir/velpatasvir/voxilaprevir) for the treatment of all chronic Hepatitis C genotypes

* Gilead Sciences Inc says has also submitted a regulatory application for SOF/VEL/VOX in United States

* Gilead Sciences Inc - Gilead has also submitted a regulatory application for SOF/VEL/VOX in United States

* Gilead Sciences Inc - Food And Drug Administration (FDA) has set a target action date under prescription drug user fee act of August 8, 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below